Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G I Murray

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Nature Medicine|April 1, 1996
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancerG I Murray, M E Duncan, P O'Neil, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.
Molecular Pathology : MP|July 31, 2001
Application of laser capture microdissection and proteomics in colon cancerL C Lawrie, S Curran, H L McLeod, et al.
Gut|November 21, 1998
Matrix metalloproteinases and their inhibitors in gastric cancerG I Murray, M E Duncan, E Arbuckle, et al.
Current Cancer Drug Targets|May 12, 2004
The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directionsP H Rooney, C Telfer, M C E McFadyen, et al.
The Journal of Pathology|September 19, 2006
Characterization and over-expression of chaperonin t-complex proteins in colorectal cancerC Coghlin, B Carpenter, S R Dundas, et al.
British Journal of Cancer|September 6, 2006
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancerB Carpenter, M McKay, S R Dundas, et al.
The Journal of Pathology|October 1, 1994
Immunohistochemical localization of glutathione S-transferases in sarcomasJ A McKay, G I Murray, S W Ewen, et al.
Cancer Letters|July 8, 1999
Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumoursY L Cheung, A C Kerr, M C McFadyen, et al.
European Journal of Biochemistry|December 16, 1998
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated formM E Duncan, J P Richardson, G I Murray, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Nature Medicine|April 1, 1996
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancerG I Murray, M E Duncan, P O'Neil, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.
Molecular Pathology : MP|July 31, 2001
Application of laser capture microdissection and proteomics in colon cancerL C Lawrie, S Curran, H L McLeod, et al.
Gut|November 21, 1998
Matrix metalloproteinases and their inhibitors in gastric cancerG I Murray, M E Duncan, E Arbuckle, et al.
Current Cancer Drug Targets|May 12, 2004
The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directionsP H Rooney, C Telfer, M C E McFadyen, et al.
The Journal of Pathology|September 19, 2006
Characterization and over-expression of chaperonin t-complex proteins in colorectal cancerC Coghlin, B Carpenter, S R Dundas, et al.
British Journal of Cancer|September 6, 2006
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancerB Carpenter, M McKay, S R Dundas, et al.
The Journal of Pathology|October 1, 1994
Immunohistochemical localization of glutathione S-transferases in sarcomasJ A McKay, G I Murray, S W Ewen, et al.
Cancer Letters|July 8, 1999
Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumoursY L Cheung, A C Kerr, M C McFadyen, et al.
European Journal of Biochemistry|December 16, 1998
Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated formM E Duncan, J P Richardson, G I Murray, et al.
Pageof 12